Article info

Download PDFPDF
Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study

Authors

  1. Address correspondence and reprint requests to: Alan N. Gordon, Arizona Gynecologic Oncology, 1300 North 12th Street, Suite 614, Phoenix, AZ 85006, USA. Email: agordonmd{at}earthlink.net

Citation

GORDON AN, FINKLER N, EDWARDS RP, et al
Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study

Publication history

  • First published September 8, 2005.
Online issue publication 
February 26, 2019

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.